GSK awards milestone payment to Isis Pharmaceuticals to develop ISIS-GSK4Rx for ocular disease

Download PDF Copy

Reviewed

Isis Pharmaceuticals, Inc.Oct 1 2014

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $1.5 million milestone payment from GSK related to the advancement of the program to develop ISIS-GSK4_Rx to treat an undisclosed ocular disease.

"Our collaboration with GSK has been very productive resulting in four drugs in development," said B. Lynne Parshall, chief operating officer at Isis. "We look forward to advancing ISIS-GSK4_Rx into clinical development and providing more information on the target and disease opportunity, which we are very excited about."

Source:

Isis Pharmaceuticals, Inc.

Posted in: Business / Finance | Disease/Infection News

Comments (0)

Download PDF Copy

Suggested Reading

Edible microbeads trap fat to support weight loss

Mentavi study validates first fully digital diagnostic pathway for adult ADHD

New treatment approach developed to prevent lupus nephritis

New study reveals long road to seizure control for people with focal epilepsy

University of Maine team develops sustainable method to cut drug production costs

WHO expands global network of trusted medical product regulators

Targeting gut signaling protein may protect against alcohol-related liver damage

Gene editing restores hearing and balance in adult mice with DFNA41 deafness

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

(Logout)

Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.